Related by context. All words. (Click for frequent words.) 79 targeted radiotherapeutic 77 novel histone deacetylase 76 pan HDAC inhibitor 75 liposomal formulation 75 non nucleoside inhibitor 75 PNP inhibitor 75 histone deacetylase inhibitor 75 JAK inhibitor 75 oral prodrug 75 HDAC Inhibitor 74 mertansine 74 receptor tyrosine kinase inhibitor 74 proteasome inhibitor 74 investigational humanized monoclonal antibody 74 selective kinase inhibitor 74 mitogen activated ERK kinase 74 Hsp# Inhibitor 73 Factor VIIa 73 orally bioavailable 73 Irinotecan 73 dasatinib Sprycel ® 73 IAP inhibitor 73 Phase #b/#a clinical 73 HCV protease inhibitor 73 multi kinase inhibitor 73 PDE4 inhibitor 73 systemic RNAi therapeutic 73 Amrubicin 73 refractory chronic lymphocytic 72 orally administered inhibitor 72 Aflibercept 72 Omacetaxine 72 IgG1 monoclonal antibody 72 dasatinib Sprycel 72 mTOR inhibitor 72 virus HCV protease inhibitor 72 MT# MEDI 72 vinca alkaloid 72 Phase Ib study 72 FOLOTYN ® 72 Epratuzumab 72 anticancer compound 72 Kinase Inhibitor 72 lexidronam injection 72 polymerase inhibitor 72 CEQ# 72 Dasatinib 72 IMiDs R 71 ALN TTR 71 KSP inhibitor 71 MAGE A3 ASCI 71 JAK2 inhibitor 71 cell lymphoma CTCL 71 vapreotide acetate 71 targeted antifolate 71 small molecule tyrosine 71 Pathway Inhibitor 71 Onconase 71 Maribavir 71 ZEVALIN ® 71 Carfilzomib 71 IL# PE#QQR 71 targeting CD# 71 Panzem R 71 Bosutinib 71 docetaxel Taxotere R 71 gefitinib Iressa 71 HSP# inhibitor 71 AAG geldanamycin analog 71 fluoropyrimidine 71 Pharmacokinetics PK 71 nucleoside analog 71 GW# [003] 71 sunitinib Sutent 71 sorafenib Nexavar 71 intranasal formulation 71 reslizumab 71 CYT# potent vascular disrupting 71 Bezielle 71 humanized monoclonal 71 Personalized Immunotherapy 71 YONDELIS 71 MGd 71 Vicinium TM 71 imatinib Gleevec ® 71 cetuximab Erbitux R 71 Vascular Disrupting Agent 71 Perifosine 71 fosbretabulin 71 PEGylated Fab fragment 71 RhuDex ® 71 prokinetic agent 71 BAY #-# 71 essential thrombocythemia ET 71 ALN PCS 71 antibody MAb 70 tumor vascular disrupting 70 Inhalation Solution 70 Traficet EN 70 PDX pralatrexate 70 Pemetrexed 70 PEG SN# 70 MEK inhibitor 70 pomalidomide 70 XL# XL# 70 radiation sensitizer 70 Iluvien ® 70 Annamycin 70 humanized monoclonal antibody 70 huN# DM1 70 HuMax CD4 70 Archexin 70 generation purine nucleoside 70 sodium glucose cotransporter 70 kinase inhibitor 70 HCV NS5B polymerase 70 Romidepsin 70 peripherally acting 70 metaglidasen 70 vinorelbine tartrate 70 Phase Ib clinical trials 70 vascular disrupting agent 70 erlotinib Tarceva ® 70 CCR5 antagonist 70 phase IIb clinical 70 selective androgen receptor modulator 70 panitumumab Vectibix 70 depsipeptide 70 ocular formulation 70 PKC# 70 darinaparsin ZIO 70 2 methoxyestradiol 70 relapsed refractory multiple myeloma 70 Kahalalide F 70 huC# DM4 70 cutaneous T 70 Pertuzumab 70 alkylating agent 70 IAP inhibitors 70 PI3K/Akt pathway inhibitor 70 Zolinza 70 selective antagonist 70 PEGylated anti 70 ADP receptor antagonist 70 Cloretazine ® 70 IMA# 70 Panzem R NCD 70 selective inhibitor 70 Squalamine 70 Cloretazine 70 Debio 70 somatostatin analogue 70 Blinatumomab 70 VitiGam 70 docetaxel Taxotere ® 70 Azedra 70 AKT inhibitor 70 sorafenib tablets 70 topically applied SEPA 70 elotuzumab 70 molecular imaging radiopharmaceutical 70 cetuximab Erbitux ® 70 thalidomide Thalomid 69 mGluR5 negative 69 lintuzumab SGN 69 generation Hsp# inhibitor 69 Ozarelix 69 Myelofibrosis 69 pan histone deacetylase 69 Ambrisentan 69 LEP ETU 69 acetonide FA 69 Ecallantide 69 tumors GIST 69 Gleevec resistant 69 Vidaza azacitidine 69 ATL# [001] 69 volociximab 69 Phase 2b Clinical Trial 69 monoclonal antibody conjugated 69 Daclizumab 69 PrevOnco 69 angiogenesis inhibitor 69 Aplidin 69 reversible inhibitor 69 investigational antiplatelet agent 69 anti angiogenic agent 69 TG# [003] 69 Xyfid TM 69 Bruton tyrosine kinase Btk 69 Allovectin 7 69 Tarceva TM 69 Pazopanib 69 arsenic trioxide injection 69 lorvotuzumab mertansine 69 denileukin diftitox 69 evaluating tivozanib 69 highly selective inhibitor 69 Dalbavancin 69 microtubule inhibitor 69 romidepsin novel 69 Liposomal 69 humanized anti 69 Interferon alfa 69 Vinorelbine 69 tubulin inhibitor 69 Epidermal Growth Factor Receptor 69 Panzem NCD 69 sulodexide 69 Pivotal Phase III 69 Tesetaxel 69 FUSILEV ® 69 Triapine 69 Voreloxin 69 alvespimycin 69 metastatic malignant 69 metastatic colorectal 69 Initiate Phase 69 mapatumumab 69 Fc fusion protein 69 Advanced Renal Cell 69 novel VDA molecule 69 novel peptide 69 leukemia AML 69 AEGR 69 Ixempra 69 YONDELIS R 69 Alfacell proprietary ribonuclease 69 small molecule Hedgehog 69 preclinical efficacy 69 rilonacept 69 dihydrochloride 69 Sapacitabine 69 ALN HPN 69 rNAPc2 69 injectable formulation 69 liposomal doxorubicin 69 MKC# MT 69 Solazed TM 69 Radezolid 69 bortezomib Velcade R 69 Novel Oral 69 PORxin TM 69 myelofibrosis polycythemia vera 69 Panzem 69 Janus Kinase 69 tanespimycin 69 Meets Primary Endpoint 69 ThermoDox R 69 SinuNase ™ 69 JAK2 Inhibitor 69 AQ4N 69 Pimavanserin 69 bendamustine 69 AVONEX ® 69 Elagolix 69 ZOLINZA 69 5 HT2A inverse 69 telomerase inhibitor drug 69 pertuzumab 69 Temsirolimus 69 PF # [002] 69 octreotide acetate 69 myelodysplastic myeloproliferative diseases 69 Iluvien TM 69 forodesine 69 Zybrestat 69 Palifosfamide 69 Tanespimycin 69 Trabectedin 69 beta 1a 69 Initiate Clinical Trial 69 MKC# MKC# PP 69 IMiDs ® 69 IMiD 68 trastuzumab DM1 T DM1 68 IMiDs ® compound 68 interferon gamma 1b 68 isoform selective 68 hypereosinophilic syndrome 68 triciribine phosphate monohydrate 68 trabectedin 68 immunomodulatory therapy 68 transthyretin TTR mediated amyloidosis 68 lymphoid malignancies 68 selective phosphodiesterase 68 TLK# 68 NS#/#A protease 68 Granted Orphan Drug 68 diarrhea predominant irritable 68 Interferon alpha 68 irreversible inhibitor 68 Silodosin 68 brivanib 68 CRMD# 68 Orally administered 68 JAK1 68 PSMA ADC 68 ceftazidime 68 Copegus ribavirin 68 Denufosol 68 Phase Ib clinical 68 VNP#M 68 Aztreonam 68 antibody MT# 68 Rebif ® 68 adalimumab Humira 68 histone deacetylase HDAC 68 potent antiproliferative 68 NXL# 68 topical gel formulation 68 investigational immunotherapy 68 delivers fluocinolone acetonide FA 68 seliciclib CYC# 68 allosteric modulator NAM 68 Receives Orphan Drug Designation 68 Romiplostim 68 TELINTRA 68 XL# anticancer compounds 68 INCB# [001] 68 immunotherapeutic agent 68 methylnaltrexone bromide 68 AVASTIN 68 Peginterferon alfa 2b 68 HGS# 68 sunitinib Sutent ® 68 bevacizumab Avastin ® 68 Angiotensin Converting Enzyme 68 Talabostat 68 Xanafide 68 Pafuramidine 68 humanised monoclonal antibody 68 treat chronic sinusitis 68 oral proteasome inhibitor 68 chimeric monoclonal antibody 68 Drug Candidate 68 Sym# 68 Safinamide 68 KRN# 68 Bruton tyrosine kinase 68 Preclinical studies suggest 68 Quinamed 68 radiotherapeutic 68 MTP inhibitor 68 Deforolimus 68 BiTE 68 recurrent glioblastoma multiforme 68 perifosine KRX 68 plasma kallikrein inhibitor 68 phase IIb study 68 Presents Preclinical 68 SAR# [004] 68 dextromethorphan quinidine 68 Gleevec imatinib mesylate 68 Onalta ™ 68 Homspera TM 68 Aurora Kinase 68 Tezampanel 68 Luteinizing Hormone Releasing Hormone 68 novel emulsion formulation 68 Guanilib 68 Proxinium TM 68 Yondelis ® 68 paclitaxel Taxol 68 Camptosar ® 68 proteasome inhibitors 68 resolvin 68 Lenalidomide 68 Sudhir Agrawal D.Phil 68 small molecule inhibitor 68 non nucleoside HCV 68 Etoposide 68 castrate resistant prostate cancer 68 superficial bladder cancer 68 MET VEGFR2 68 PI3K inhibitor 68 AEG# 68 Soliris eculizumab 68 protein kinase inhibitor 68 Troxatyl 68 Glufosfamide 68 intravesical instillation 68 novel prodrug 68 oral renin inhibitor 68 TLR8 agonist 68 Presents Preclinical Data 68 acyclovir Lauriad R 68 Myocet 68 samarium Sm 68 Erlotinib 68 neratinib 68 Aclidinium 68 long acting muscarinic 68 thetreatment 68 relapsed leukemia 68 Initiates Clinical 68 Enzastaurin 68 HQK 68 Ceflatonin 68 hypoxia activated prodrug 68 Initiates Clinical Trial 68 Aurora kinase 68 Junovan TM 68 Camptosar ® irinotecan 68 novel topoisomerase 68 Hedgehog pathway inhibitor 68 TRX1 68 Elvitegravir 68 CLL SLL 68 Phase III Clinical Trial 68 Civacir 68 assessing T DM1 68 Initiates Enrollment 68 BrachySil TM 68 MT#/MEDI-# 68 herpetic keratitis 68 selective agonist 68 verteporfin 68 histone deacetylase 68 antisense inhibitor 68 HuMax EGFr 68 Diabetic Macular Edema DME 68 bleomycin 68 gemcitabine Gemzar ® 68 Nanobody 68 highly selective endothelin 68 polycythemia vera essential thrombocythemia 68 TRO# 67 selective modulator 67 Nexavar ® 67 oral Hsp# inhibitor 67 Vidofludimus 67 orally dosed 67 vorinostat 67 xanthine oxidase inhibitor 67 developing Zerenex ferric 67 PEP# [003] 67 Gemzar ® 67 ALGRX 67 ongoing Phase 1b 67 Zorbtive TM 67 Neulasta ® 67 oral anti arrhythmic 67 Dapagliflozin 67 refractory cutaneous T 67 Completes Patient Enrollment 67 Xeloda ® 67 Phase 2a Clinical Trial 67 CCX# 67 Interferon beta 67 mu opioid receptor antagonist 67 Neulasta R 67 Zemiva TM 67 BiovaxID TM 67 Phase #/#a trial 67 opioid induced constipation OIC 67 HDACi 67 5 FU leucovorin 67 INSPIRE Trial Phase III 67 Epirubicin 67 FOLFOX6 67 Cutaneous T 67 VQD 67 metastatic hormone refractory 67 LymphoStat B TM 67 tumor xenograft models 67 trastuzumab Herceptin R 67 kidney urologic 67 Zenvia ™ 67 Akt inhibitor 67 antisense oligonucleotide 67 Ceftaroline 67 Friedreich Ataxia FRDA 67 CYC# 67 5 HT3 antagonist 67 Laquinimod 67 topically administered 67 OMNARIS HFA 67 Aliskiren 67 polycythemia vera PV 67 ELACYT 67 peptibody 67 Monoclonal Antibody 67 II Clinical Trial 67 oral candidiasis 67 PEGylated interferon beta 1a 67 phase III isavuconazole 67 oral nucleoside analogue 67 ara C 67 Decitabine 67 topoisomerase II inhibitor 67 Ceflatonin R 67 Phase IIa Clinical Trial 67 subcutaneous formulation 67 XmAb ® 67 multicenter Phase II 67 Inhalation Aerosol 67 potently inhibit 67 intravesical infusion therapy 67 MORAb 67 INVANZ 67 aurora kinase 67 novel oral anticoagulant 67 Exherin TM 67 Velcade bortezomib 67 gastrointestinal disorders ATI 67 Chronic Lymphocytic Leukemia CLL 67 Cyclooxygenase Inhibiting Nitric Oxide 67 Onalta 67 anticancer agent 67 systemic anaplastic large 67 Patients Treated With 67 TKB# 67 ZACTIMA 67 DB# [003] 67 GRN# 67 nanopharmaceutical 67 docetaxel Taxotere 67 Vidaza R 67 FOLFOX6 chemotherapy regimen 67 alemtuzumab Campath 67 SPRYCEL ® 67 developing Bicifadine serotonin 67 Azacitidine 67 Tesmilifene 67 meropenem 67 immunomodulating 67 Trofex 67 advanced metastatic renal 67 triphendiol 67 investigational compound 67 GRN#L 67 Phase IIa trials 67 RELOVAIR ™ 67 ixabepilone 67 HuMax 67 GLP toxicology studies 67 Genasense ® oblimersen 67 amrubicin 67 luteinizing hormone releasing 67 SinuNase TM 67 nilotinib Tasigna ® 67 familial amyloidotic polyneuropathy FAP 67 M2 subunit 67 brand ciclesonide HFA 67 RNAi Therapeutic 67 Phase IIb clinical trials 67 bevacizumab Avastin R 67 Dacogen decitabine 67 severe hypercholesterolemia 67 bortezomib Velcade 67 Vandetanib 67 phase IIa clinical 67 PRTX 67 EndoTAGTM 1 67 sodium thiosulfate STS 67 Prolongs Survival 67 ALN TTR# 67 Granulocyte Colony Stimulating Factor 67 Pralatrexate 67 investigational oral inhibitor 67 Ocrelizumab 67 Evoltra ® 67 Nexavar sorafenib 67 HGS ETR1 mapatumumab 67 demonstrated antitumor activity 67 Mitoxantrone 67 initiated Phase Ib 67 autologous cellular immunotherapy 67 AEZS 67 Lubiprostone 67 NMDA antagonist 67 Tocilizumab 67 inhibitor RG# 67 PLK1 SNALP 67 Phase IIb Trial 67 HCD# [002] 67 non nucleoside 67 orally inhaled migraine 67 signal transduction inhibitor 67 Tasimelteon 67 accumulate preferentially 67 hepatitis C HCV 67 tafamidis 67 Elesclomol 67 investigational oral hepatitis C 67 intravenously administered 67 Degarelix 67 TNF Tumor Necrosis Factor 67 Moxifloxacin 67 Hycamtin ® 67 novel immunomodulatory 67 retaspimycin hydrochloride 67 OHR/AVR# 67 CORT # 67 HCV protease 67 compound AEZS 67 Bendamustine 67 NS5A inhibitor 67 selectively inhibits 67 Cloretazine R 67 fluocinolone acetonide 67 nilotinib Tasigna 67 stable nucleic acid 67 epithelial tumors 67 entinostat 67 teriflunomide 67 solithromycin 67 estrogen receptor antagonist 67 Kamada AAT 67 Polymerase Inhibitor 67 Troxatyl TM 67 rHuPH# recombinant human 67 corticosteroid dexamethasone 67 Docetaxel 67 proprietary polysaccharide 67 Varespladib 67 R Saizen R 67 chemotherapy induced neutropenia 67 topical gel containing 67 renin inhibitor 67 Antiangiogenic 67 iobenguane 67 EZN 67 Preclinical Data 67 including eniluracil ADH 67 EGFR HER2 67 Marqibo TM 67 TO AVOID PREGNANCY WHILE 67 cilengitide 67 LE SN# 67 PD LID 67 Antitumor Activity 67 BAL# [002] 67 CA4P 67 HepDirect prodrug 67 HCV RNA polymerase 67 rasagiline tablets 67 TAFA# 67 Carboplatin 67 INCB# [003] 67 lucinactant 67 immunotherapeutic 66 rxRNA 66 relapsing multiple sclerosis 66 REG2 66 Anavex #-# 66 MGCD# [001] 66 CD3 monoclonal antibody 66 recurrent NSCLC 66 NKTR 66 FOLFOX chemotherapy 66 multikinase inhibitor 66 Zenvia Phase III 66 ibritumomab tiuxetan 66 CRx 66 PRT# 66 SNT MC# 66 acid phosphatase PAP 66 BiTE ® 66 lenalidomide Revlimid R 66 oncolytic virus therapies 66 ORENCIA ® 66 Hedgehog Pathway Inhibitor 66 Phase #b/#a trial 66 ILUVIEN ® 66 cutaneous T cell 66 biomodulator 66 Bortezomib 66 IRX 2 66 JZP 66 HGS ETR1 66 tyrosine kinase inhibitor TKI 66 gastrointestinal stromal tumors GIST 66 radiolabeled 66 phase Ib clinical 66 inhaled formulation 66 QUADRAMET R 66 Onrigin 66 PEGylated interferon 66 Clofarabine 66 phase IIb trial 66 acyclovir Lauriad ® 66 BiTE R 66 synthetic retinoid 66 phase IIa 66 chronic eosinophilic leukemia 66 Gemcitabine 66 Mipomersen 66 visilizumab 66 gemcitabine Gemzar 66 Bevacizumab 66 Solazed ™ 66 HGS ETR2 66 Alkeran 66 hormone LHRH antagonist 66 Immunotherapeutic 66 SCH # 66 Aplidin R 66 tiuxetan 66 selective adenosine 66 alefacept 66 Anidulafungin 66 ENMD # 66 MEK Inhibitor 66 histamine dihydrochloride 66 Androxal TM 66 Onalta TM 66 sodium Injection 66 small molecule glucokinase 66 HER2 antibody 66 OncoVex 66 FDA APPROVES 66 Complicated Skin 66 Ganciclovir 66 paclitaxel Taxol ® 66 HDAC inhibitor 66 RhuDex TM 66 Sanvar R 66 Metastatic Melanoma 66 R sorafenib tablets 66 histone deacetylase HDAC inhibitors 66 Tasigna nilotinib 66 tiapamil 66 Initiates Phase II 66 Pirfenidone 66 intravenous acetaminophen 66 BRAF inhibitor 66 EndoTAG 66 torezolid 66 Tyrosine Kinase Inhibitor 66 vascular disrupting agents 66 Golimumab 66 BCG refractory carcinoma 66 favorable pharmacokinetic profile 66 Diabetic Macular Edema 66 ATL/TV# 66 radezolid 66 brivaracetam 66 lumiliximab 66 potently inhibits 66 EOquin TM 66 Aptivus ® 66 Gel repository corticotropin injection 66 p# MAP kinase inhibitor 66 Ofatumumab 66 Fodosine 66 immunotherapeutic vaccine 66 KNS # 66 Alocrest 66 liposome injection 66 aurora kinase inhibitor 66 LY# [003] 66 hydroxamic acid 66 N acetylgalactosamine 6 66 Gefitinib 66 Onco TCS 66 investigational monoclonal antibody 66 Campath alemtuzumab 66 Enzyme Replacement Therapy 66 JAK inhibitors 66 Interferon beta 1a 66 Xcytrin R 66 systemic fungal infections 66 induced macular edema 66 2 inhibitor CYT# 66 IIa trial 66 Fx #A 66 Phase IIa trial 66 CD# monoclonal antibody 66 CTAP# Capsules 66 HIV integrase inhibitor 66 obatoclax 66 tigecycline 66 gastrointestinal stromal tumors 66 OMP #R# 66 pharmacokinetic PK study 66 Tumor Necrosis Factor 66 indolent NHL 66 Apoptone 66 radiolabeled monoclonal antibody 66 Alzhemed TM 66 selective orally bioavailable 66 R#/MEM # 66 itraconazole Sporanox 66 Eltrombopag 66 NVA# 66 Randomized Phase 66 SUTENT ® 66 metastatic colorectal carcinoma 66 broad spectrum cephalosporin 66 fluoroquinolone antibiotic 66 Kuvan sapropterin dihydrochloride 66 refractory AML 66 mRCC 66 Deferiprone 66 EOquin 66 GVAX ® 66 relapsed multiple myeloma 66 Parathyroid Hormone 66 refractory APL 66 immune globulin intravenous 66 Cardiotoxicity 66 Solorel TM 66 CINTREDEKIN BESUDOTOX 66 cisplatin gemcitabine 66 DFMO 66 generation antisense inhibitor 66 Ixabepilone 66 Investigational Treatment 66 Muraglitazar 66 cannabinor 66 alpha antagonist 66 Cannabinor 66 registrational trial 66 Investigational Oral 66 LBH# 66 RhuDex R 66 omacetaxine mepesuccinate 66 MOVIPREP R 66 Exherin 66 Thiarabine 66 Aurexis 66 Vaprisol 66 Phase Ib II 66 Mg Usa 66 Factor VIIa inhibitor 66 opioid induced bowel dysfunction 66 Combination REOLYSIN R 66 TLR9 agonist 66 HER2 positive metastatic breast 66 RAPTIVA 66 Polymer Microspheres 66 efaproxiral 66 Phase 1b clinical 66 Sphingomab TM 66 R bendamustine hydrochloride 66 Cleviprex TM clevidipine 66 OncoGel 66 Plicera 66 evaluating satraplatin 66 Tofacitinib 66 BRIM2 66 Announces Poster Presentations 66 Vicriviroc 66 UPLYSO 66 T#I [002] 66 pegfilgrastim 66 compound perifosine 66 investigational pan BCR 66 Clevudine 66 prucalopride 66 Fludara ® 66 immune modulating 66 DOXIL 66 miconazole Lauriad ® 66 HepaSphere 66 Platinol ® 66 Chemokine Receptor 66 #mg/#mg 66 midstage trials 66 Mycophenolate Mofetil 66 Dyloject TM 66 monoclonal anti 66 Cotara R 66 IMPDH inhibitor 66 immunomodulator 66 LHRH agonists 66 LHRH receptor positive 66 Crizotinib 66 telomerase therapeutic 66 Solazed 66 Octreolin 66 novel orally bioavailable 66 Zenvia TM 66 cortisol synthesis 66 sapropterin dihydrochloride 66 therapeutic monoclonal antibody 66 SIR Spheres 66 inhalation powder 66 modified glutathione analog 66 ENMD 66 sargramostim 66 papillary renal cell carcinoma 66 Firazyr 66 oral antiviral 66 Bafetinib 66 nucleotide analog 66 OvaRex R 66 CYP#A# CYP#D# 66 delafloxacin 66 #I TM# 66 vinca alkaloids 66 BCG refractory 66 HFA MDI 66 OMP #M# 66 PROSTASCINT R 66 Tyrima 66 humanised antibody 66 CB2 selective receptor agonist 66 Nasdaq PARD 66 GAMMAGARD 66 oral ridaforolimus 66 REMINYL ® 66 Besivance 66 DNA demethylating agent 66 crizotinib PF # 66 sitaxsentan 65 PXD# 65 Radiation Therapy SIRT 65 Liprotamase 65 ANYARA 65 Anticalin R 65 oxazolidinone 65 Eculizumab 65 Aganocide ® 65 immunotoxin 65 Preclinical studies 65 CRF1 receptor antagonist 65 bortezomib Velcade ® 65 ACHN 65 dose escalation clinical 65 PEG IFN 65 mGluR2 positive 65 vesicular monoamine transporter 65 acadesine 65 Bucindolol 65 VEGF inhibitors 65 monoclonal antibody MAb 65 Spiegelmer ® 65 Xcellerated T Cells 65 nephropathic cystinosis 65 apoptosis inducer 65 BiTE antibody 65 Rebif interferon beta 1a 65 selective immunoproteasome inhibitor 65 Elotuzumab 65 #HT# 65 RGB # 65 Orally Active 65 Navelbine ® 65 Phase 2a trial 65 CCR9 antagonist 65 Amplimexon 65 etanercept Enbrel 65 Bremelanotide 65 busulfan 65 hyaluronidase enzyme 65 lexidronam injection PROSTASCINT 65 Valopicitabine 65 Oral Fingolimod 65 toenail onychomycosis 65 adecatumumab MT# 65 Files Investigational 65 anti PlGF 65 malignant ascites 65 CD# CEA 65 5 fluorouracil leucovorin 65 Reports Preclinical Data 65 humanized monoclonal antibodies 65 modulator SERM 65 lenalidomide Revlimid ® 65 Phase IIb Clinical Trial 65 p# inhibitor 65 SYN# 65 MNTX 65 ON #.Na 65 glioblastoma multiforme GBM 65 DermaVir Patch 65 leukemia CLL 65 subependymal giant cell 65 Granisetron 65 alpha folate receptor 65 non alcoholic steatohepatitis 65 systemically administered 65 RNA antagonist 65 Darusentan 65 Initiates Phase III 65 Taxotere docetaxel 65 Omacetaxine mepesuccinate 65 octreotide implant 65 Avastin bevacizumab 65 Panzem ® 65 Prodarsan R 65 Aurora kinase inhibitor 65 Multiple Ascending Dose 65 OncoVEX GM CSF 65 HCV polymerase 65 dexamethasone Decadron 65 lenalidomide Revlimid 65 delta isoform 65 Demonstrates Significant 65 agent VDA 65 SERMs 65 Cimzia ® certolizumab pegol 65 Removab 65 beta interferons 65 Capecitabine 65 class anticancer quinolone